Scholar Rock provides 2024 pipeline update; Phase 3 SMA trial topline data expected Q4 2024

Scholar Rock Holding Corp

Cash and equivalents of ~$280M as of Dec 31, 2023; projected to fund operations into H2 2025.
Enrollment completed for apitegromab pivotal Phase 3 SAPPHIRE in SMA; topline data expected Q4 2024.
Phase 2 proof-of-concept trial of apitegromab with GLP-1 RA in obesity to start mid-2024.
SRK-439 IND for obesity planned in 2025; preclinical data at Keystone Symposia in Feb 2024.
Presenting at J.P. Morgan Healthcare Conference on Jan 9, 2024 at 1:30 p.m. PT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.